Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
International Journal of Clinical Oncology, 06/12/2012
Frustaci S et al. – Fractionation of doses and the use of less toxic and more convenient derivatives are the rationales for this new combination. The MTD (mg/m2) was: D, 30 and O, 70, both on days 1 and 8, i.v.; C 1000 per day, days 2–15, p.o.; all given every 3weeks. A cooperative phase II study has been opened.